vs
ANI PHARMACEUTICALS INC（ANIP）与南玻集团（CSGS）财务数据对比。点击上方公司名可切换其他公司
南玻集团的季度营收约是ANI PHARMACEUTICALS INC的1.3倍（$323.1M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 2.2%，领先9.0%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 2.0%），南玻集团自由现金流更多（$55.8M vs $29.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 4.6%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
ANIP vs CSGS — 直观对比
营收规模更大
CSGS
是对方的1.3倍
$247.1M
营收增速更快
ANIP
高出27.6%
2.0%
净利率更高
ANIP
高出9.0%
2.2%
自由现金流更多
CSGS
多$26.7M
$29.1M
两年增速更快
ANIP
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $323.1M |
| 净利润 | $27.5M | $7.0M |
| 毛利率 | — | 50.0% |
| 营业利润率 | 14.1% | 9.0% |
| 净利率 | 11.1% | 2.2% |
| 营收同比 | 29.6% | 2.0% |
| 净利润同比 | 367.5% | -79.7% |
| 每股收益（稀释后） | $1.14 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPCSGS
| Q4 25 | $247.1M | $323.1M | ||
| Q3 25 | $227.8M | $303.6M | ||
| Q2 25 | $211.4M | $297.1M | ||
| Q1 25 | $197.1M | $299.5M | ||
| Q4 24 | $190.6M | $316.7M | ||
| Q3 24 | $148.3M | $295.1M | ||
| Q2 24 | $138.0M | $290.3M | ||
| Q1 24 | $137.4M | $295.1M |
净利润ANIPCSGS
| Q4 25 | $27.5M | $7.0M | ||
| Q3 25 | $26.6M | $20.5M | ||
| Q2 25 | $8.5M | $12.3M | ||
| Q1 25 | $15.7M | $16.1M | ||
| Q4 24 | $-10.3M | $34.5M | ||
| Q3 24 | $-24.2M | $19.1M | ||
| Q2 24 | $-2.3M | $13.8M | ||
| Q1 24 | $18.2M | $19.5M |
毛利率ANIPCSGS
| Q4 25 | — | 50.0% | ||
| Q3 25 | — | 48.1% | ||
| Q2 25 | — | 49.5% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | 51.3% | ||
| Q3 24 | — | 49.4% | ||
| Q2 24 | — | 47.3% | ||
| Q1 24 | — | 46.5% |
营业利润率ANIPCSGS
| Q4 25 | 14.1% | 9.0% | ||
| Q3 25 | 15.9% | 10.0% | ||
| Q2 25 | 6.6% | 10.0% | ||
| Q1 25 | 13.3% | 9.8% | ||
| Q4 24 | -2.3% | 13.4% | ||
| Q3 24 | -13.8% | 10.8% | ||
| Q2 24 | 3.7% | 8.8% | ||
| Q1 24 | 14.8% | 10.8% |
净利率ANIPCSGS
| Q4 25 | 11.1% | 2.2% | ||
| Q3 25 | 11.7% | 6.7% | ||
| Q2 25 | 4.0% | 4.1% | ||
| Q1 25 | 8.0% | 5.4% | ||
| Q4 24 | -5.4% | 10.9% | ||
| Q3 24 | -16.3% | 6.5% | ||
| Q2 24 | -1.7% | 4.8% | ||
| Q1 24 | 13.2% | 6.6% |
每股收益（稀释后）ANIPCSGS
| Q4 25 | $1.14 | $0.24 | ||
| Q3 25 | $1.13 | $0.73 | ||
| Q2 25 | $0.36 | $0.44 | ||
| Q1 25 | $0.69 | $0.57 | ||
| Q4 24 | $-0.45 | $1.20 | ||
| Q3 24 | $-1.27 | $0.67 | ||
| Q2 24 | $-0.14 | $0.48 | ||
| Q1 24 | $0.82 | $0.68 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $180.0M |
| 总债务越低越好 | — | $539.5M |
| 股东权益账面价值 | $540.7M | $283.7M |
| 总资产 | $1.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 1.90× |
8季度趋势，按日历期对齐
现金及短期投资ANIPCSGS
| Q4 25 | $285.6M | $180.0M | ||
| Q3 25 | $262.6M | $158.4M | ||
| Q2 25 | $217.8M | $145.9M | ||
| Q1 25 | $149.8M | $136.0M | ||
| Q4 24 | $144.9M | $161.8M | ||
| Q3 24 | $145.0M | $118.4M | ||
| Q2 24 | $240.1M | $110.4M | ||
| Q1 24 | $228.6M | $120.8M |
总债务ANIPCSGS
| Q4 25 | — | $539.5M | ||
| Q3 25 | — | $538.6M | ||
| Q2 25 | — | $537.8M | ||
| Q1 25 | — | $537.6M | ||
| Q4 24 | — | $538.5M | ||
| Q3 24 | — | $539.5M | ||
| Q2 24 | — | $540.5M | ||
| Q1 24 | — | $541.5M |
股东权益ANIPCSGS
| Q4 25 | $540.7M | $283.7M | ||
| Q3 25 | $505.8M | $289.5M | ||
| Q2 25 | $436.8M | $290.7M | ||
| Q1 25 | $418.6M | $283.1M | ||
| Q4 24 | $403.7M | $282.6M | ||
| Q3 24 | $405.9M | $288.4M | ||
| Q2 24 | $455.8M | $273.3M | ||
| Q1 24 | $452.0M | $269.3M |
总资产ANIPCSGS
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $920.8M | $1.4B | ||
| Q1 24 | $914.5M | $1.3B |
负债/权益比ANIPCSGS
| Q4 25 | — | 1.90× | ||
| Q3 25 | — | 1.86× | ||
| Q2 25 | — | 1.85× | ||
| Q1 25 | — | 1.90× | ||
| Q4 24 | — | 1.91× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | — | 2.01× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $59.2M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $55.8M |
| 自由现金流率自由现金流/营收 | 11.8% | 17.3% |
| 资本支出强度资本支出/营收 | 0.5% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.10× | 8.46× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $141.4M |
8季度趋势，按日历期对齐
经营现金流ANIPCSGS
| Q4 25 | $30.4M | $59.2M | ||
| Q3 25 | $44.1M | $47.9M | ||
| Q2 25 | $75.8M | $37.3M | ||
| Q1 25 | $35.0M | $11.5M | ||
| Q4 24 | $15.9M | $82.5M | ||
| Q3 24 | $12.5M | $39.5M | ||
| Q2 24 | $17.4M | $43.1M | ||
| Q1 24 | $18.3M | $-29.4M |
自由现金流ANIPCSGS
| Q4 25 | $29.1M | $55.8M | ||
| Q3 25 | $38.0M | $43.9M | ||
| Q2 25 | $71.8M | $34.6M | ||
| Q1 25 | $32.5M | $7.1M | ||
| Q4 24 | $13.5M | $76.6M | ||
| Q3 24 | $7.7M | $32.0M | ||
| Q2 24 | $13.0M | $38.8M | ||
| Q1 24 | $13.7M | $-34.1M |
自由现金流率ANIPCSGS
| Q4 25 | 11.8% | 17.3% | ||
| Q3 25 | 16.7% | 14.5% | ||
| Q2 25 | 34.0% | 11.6% | ||
| Q1 25 | 16.5% | 2.4% | ||
| Q4 24 | 7.1% | 24.2% | ||
| Q3 24 | 5.2% | 10.8% | ||
| Q2 24 | 9.4% | 13.4% | ||
| Q1 24 | 10.0% | -11.6% |
资本支出强度ANIPCSGS
| Q4 25 | 0.5% | 1.1% | ||
| Q3 25 | 2.7% | 1.3% | ||
| Q2 25 | 1.9% | 0.9% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 1.3% | 1.9% | ||
| Q3 24 | 3.2% | 2.5% | ||
| Q2 24 | 3.2% | 1.5% | ||
| Q1 24 | 3.3% | 1.6% |
现金转化率ANIPCSGS
| Q4 25 | 1.10× | 8.46× | ||
| Q3 25 | 1.66× | 2.34× | ||
| Q2 25 | 8.87× | 3.04× | ||
| Q1 25 | 2.23× | 0.71× | ||
| Q4 24 | — | 2.39× | ||
| Q3 24 | — | 2.07× | ||
| Q2 24 | — | 3.12× | ||
| Q1 24 | 1.00× | -1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
